๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Casdatifan

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 5 trials in our USA, UK, China and Ireland registers that name Casdatifan as an intervention. Synced 24 Sep 2026
5Trials tracked
5Recruiting now
3Lead sponsors
4Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Casdatifan is named as a drug or biological intervention in 5 clinical trials in our USA, UK, China and Ireland trial registers, 5 of which are recruiting. Lead sponsors include Arcus Biosciences, Inc. (3), Bristol-Myers Squibb (1) and Pfizer (1). Registered phases: Phase 1/2, Phase 1 and Phase 3. Conditions studied include Advanced Renal Cell Carcinoma (RCC); Metastatic Clear Cell Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma.

01

Clinical trials of Casdatifan

5 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT07011719 Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma (ClinicalTrials.gov ↗)
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Phase 3 Recruiting Arcus Biosciences, Inc. UK, USA
NCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer (ClinicalTrials.gov ↗)
Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer
Phase 1/2 Recruiting Pfizer USA, China
NCT07293351 A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Advanced Renal Cell Carcinoma (RCC)
Phase 1/2 Recruiting Bristol-Myers Squibb Ireland, UK, USA, China
NCT05536141 A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ClinicalTrials.gov ↗)
Clear Cell Renal Cell Carcinoma, Solid Tumors
Phase 1 Recruiting Arcus Biosciences, Inc. USA
NCT07751250 Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function (ClinicalTrials.gov ↗)
Healthy Participants, Hepatic Impairment
Phase 1 Recruiting Arcus Biosciences, Inc. USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

11 conditions
Condition (as registered)Trials
Advanced Renal Cell Carcinoma (RCC)1
Metastatic Clear Cell Renal Cell Carcinoma1
Advanced Clear Cell Renal Cell Carcinoma1
Clear Cell Renal Cell Carcinoma1
Solid Tumors1
Healthy Participants1
Hepatic Impairment1
Carcinoma, Renal Cell1
Advanced Renal Cell Carcinoma1
Renal Cancer1
Renal Neoplasm1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Arcus Biosciences, Inc.3
Bristol-Myers Squibb1
Pfizer1
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Casdatifan works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Casdatifan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.